4Vane JR,Bakhle YS,Botting RM.Cyclooxygenase 1 and 2.Ann Rev Pharmacol Toxicol,1998,38:97-120.
5Cipllone F,Patrignani P,Greco A,et al.Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.Circulation,1997,96:1109-6.
6Weber AA,Zimmermann KC,Meyer-Kirchrath J,et al.Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.Lancet,1999,353:900.
8Karim S,Habib A,Levy-Toledano S,et al.Cyclooxygenase-1 and-2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane.J Biol Chem,1996,271:12042-8.
9Helgason CM,Tortorice KL,Winkler SR,et al.Aspirin response and failure in cerebral infarction.Stroke,1993,24:345-50.
7Marc K H, Perry V H. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? [J]. Circulation, 2002,105(14) :1620-1622.
8Eikelboom J W, Jack H, Jeffrey W I,et al . Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events[J]. Circulation, 2002, 105(14) :1650-1655.
9Gum P A, Marchant K K, Welsh P A, et al . A prospective,blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease[J]. JACC, 2003, 41(6) :961-965.
10Mueller C, Roskamm H, Neumann F J, et al . A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents [J].JACC,2003,41(6) :969-973.
4Omlczuk MO, Wang CC, Pope DG. Influence of micronization on compaction properties of an investigational drug using tablet index a- nalysis[ J]. Eur J Pharm biopharm, 1997,43 ( 1 ) :95 - 100.
